Abstract 267P
Background
Homologous recombination deficiency (HRD) score serves as a promising biomarker to identify patients who are eligible for treatment with PARP inhibitor (PARPi). Previous studies have suggested a 3-biomarker Genomic Instability Score (GIS) threshold of ≥42 is a valid biomarker to predict response to PARPi in patients with ovarian cancer. However, the GIS threshold for prostate cancer (PCa) is still lacking. Here, we conducted an exploratory analysis to investigate an appropriate GIS score and to evaluate its ability to predict response to PARPi in prostate cancer patients.
Methods
A total of 225 patients with PCa were included in this study. Tumor tissue specimens were collected for targeted next-generation sequencing for homologous recombination repair (HRR) genes and promoter methylation analysis. GIS score was calculated based on over 50,000 single-nucleotide polymorphisms (SNP) distributed across the human genome, incorporating three SNP-based assays: loss of heterozygosity, telomeric allelic imbalance, and large-scale state transition. The HRD score threshold was set at the 5th percentile of the GIS scores in our cohort of known BRCA1/2-deficient tumors which is the method used to define the HRD threshold in breast and ovarian cancer.
Results
In our cohort, 22 patients (9.78%) had BRCA1/2 mutations or BRCA1/2 promoter methylation, with additional 32 patients (14.22%) carrying mutations in HRR genes. The median HRD score was 2 (ranged from 0 to 78) in total cohort which is much lower than that of in breast and ovarian cancer. The 5th percentile of HRD scores was 9 in the BRCA1/2-deficient cohort and consequently high HRD was defined as HRD scores >9. In the 12 patients who received PARPi in our cohort, 8 patients with a high HRD score achieved a disease control rate of 83.3%. In addition, 4 patients with a low HRD score but with mutations in HRR genes other than BRCA1/2 achieved a disease control rate of 25.0%.
Conclusions
HRD positive, defined as GIS score >9, may be an appropriate threshold to predict the likelihood of response to PARPi in prostate cancer. Prospective, and large sample clinical trials will be needed to confirm our findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
J. Wang.
Funding
China Anti-Cancer Association-Hengrui PARP Inhibitor Cancer Research Fund (Phase I).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract